Humanwell medical and biological products are approved to enter the clinical phase II trial

Humanwell pharmaceutical announced today that the recombinant plasmid hepatocyte growth factor injection developed by Wuhan Guanggu humanwell biomedical Co., Ltd (humanwell pharmaceutical holds 32.52% of the equity, which is the largest shareholder of humanwell pharmaceutical) was approved for phase II clinical trials by the approval for clinical trials of drugs issued by the State Food and drug administration According to the company, the recombinant plasmid hepatocyte growth factor injection is a biological product with the expression plasmid as the carrier and hepatocyte growth factor as the treatment gene, which can effectively promote angiogenesis, mainly used for limb artery occlusion, limb rest pain, ischemic ulcer and other serious vascular diseases It is reported that the drug was jointly developed by the Academy of Military Medical Sciences and Wuhan humanwell Pharmaceutical Group, and is now in the experimental stage Wuhan Optics Valley humanwell has a platform for humanwell pharmaceutical and Academy of Military Medical Sciences to jointly focus on the development of genetically engineered drugs At present, it has carried out 11 research and development projects led by Academician Wu Zuze, among which five new biological products of the first class are the most interesting, and the two heavyweight genetic biological drugs are the most advanced in research and development The first is the recombinant drugs approved to enter the second phase of clinical practice The first is the recombinant adenovirus hepatocyte growth factor project, which has also entered the second phase of clinical trials Both products are expected to be listed within three to five years and make substantial contributions to the company's performance (BIOON Com)